- Home
- Companies
- usa massachusetts
- gene therapy s
Show results for
Refine by
Gene Therapy S Suppliers In Usa Massachusetts
11 companies found
based inBall Ground, GEORGIA (US) (USA)
The MVE range of cryogenic freezers and aluminum dewars have been engineered for ultimate reliability and maximizing hold times at the ultra-low temperatures vital to the preservation of critical human and animal tissues and vaccines. We supply a ...
based inFoxborough, MASSACHUSETTS (USA)
Suono Bio is a biotechnology company harnessing our proprietary delivery platform to transform treatment of intractable diseases. Suono Bio is a on a mission to harness its proprietary therapeutic platform to transform treatment of ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
At Revvity, we work with you to expedite the development of gene therapy vectors. ...
based inGaithersburg, MASSACHUSETTS (USA)
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly ...
Selecta Biosciences’ immune tolerance platform, ImmTOR, is designed to give rise to antigen-specific immunity, mitigating unwanted immune ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
based inSeattle, WASHINGTON (USA)
We believe we are entering a new era of medicine. The ability to modify genes and use cells as medicines provides new tools to meaningfully change the outcome of many human diseases. Early pioneers have made good progress, but most of what we can ...
based inBoston, MASSACHUSETTS (USA)
Neoclease is at the forefront of advancing gene editing technologies with a mission to transform healthcare by curing genetic diseases rather than just treating them. Utilizing a bespoke approach, the company develops tailored nucleases designed to ...
based inWatertown, MASSACHUSETTS (USA)
Dyno Therapeutics is a Cambridge based, VC-backed biotech startup that uses next-gen DNA technologies and machine learning to engineer Adeno-associated Virus (AAV) capsids for effective delivery of gene therapies. We are inventing new ways to design ...
Our CapsidMap™ platform uses AI to systematically and rapidly optimize AAV capsids, overcoming the limitations of naturally occurring virus capsids by improving targeting ability, payload size, immune evasion and manufacturability. By building ...
based inVillejuif, FRANCE
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...
based inCambridge, MASSACHUSETTS (USA)
Obsidian Therapeutics is using its proprietary cytoDRiVE platform to harness the power of proteins to engineer precision medicines. Our lead internal programs are focused on engineering TIL therapies that are more effective and safer for patients ...
Engineered with membrane-bound IL15, Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy, Drives improved persistence, IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® ...
based inWaltham, MASSACHUSETTS (USA)
MaxCyte. SeQure Dx, Inc. is applying state of the art genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Our core technologies, GUIDE-seq and ONE-seq, enable identification of ...
GUIDE-seq and ONE-seq are used to nominate potential off-target editing sites in cellular models and free DNA, respectively. ONE-seq has the advantages that it can be used to assess adenine and cytosine base editors, it allows variant-aware ...
